

Serum Prolactin As A Diagnostic Marker For Uterine Fibroid

Thesis

Submitted for complete fulfillment of Master
Degree in **Obstetrics and Gynaecology**

By

Pance Mohamed Othman Ahmed

M.B.B.ch. Cairo University.

Resident of Obstetrics & Gynaecology Sohag teaching hospital

Supervised by

Prof. Dr. Hany Hassan Moustafa

*Professor of Obstetrics & Gynaecology
Faculty of Medicine - Cairo University*

Prof. Dr. Iman Atef Mandor

*Professor of Clinical and Chemical Pathology
Faculty of Medicine - Cairo University*

Dr. Hoda Mohamed Abd El-Aal

*Lecturer in Obstetrics & Gynaecology
Faculty of Medicine - Cairo University*

*Faculty of Medicine - Cairo University
2012*

Abstract

Objectives: To evaluate the use of serum prolactin as a tumor marker in diagnosing uterine fibroid(s).

Methods: A case control study was carried out from March 2010 to October 2010, at El Kasr El-Aini University maternity Hospital. Thirty patients with uterine fibroid(s) and 30 healthy normal women were involved in the study. Blood samples were collected from uterine fibroid patients before and after surgery. The serum prolactin was measured by ELISA technique.

Results: The serum of patients with uterine fibroid before surgery showed an elevated prolactin level (57.43 ± 57.85) compared with their prolactin after surgery (21.16 ± 16.04), and with the control group (12.43 ± 4.67). This also increased with increasing the fibroid number, size and duration of fibroid related symptoms, independently of the site or the type of the fibroid.

Conclusion: Serum prolactin can be used as an adjuvant biochemical marker to confirm the diagnosis of uterine fibroid(s).

Keywords: Uterine fibroid, prolactin, leiomyoma, tumor markers.




First, thanks are all due to Allah for Blessing this work until it has reached its end, as a part of his generous help throughout our life.

I am deeply grateful to Prof. Dr. Hany Hassan Moustafa, Professor of Obstetric and Gynaecology, Faculty of Medicine, Cairo University for sponsoring this work, and his keen supervision.

I am also greatly indebted to Dr. Hoda Mohamed Abd El-Aal, Lecturer of Obstetric and Gynaecology, Faculty of Medicine, Cairo University, for her great supervision, great help, available advises, continuous encouragement and without her support it was impossible for this study to be achieved in this form. I had the privilege to benefit from her great knowledge, and it is an honor to work under her guidance and supervision.

I would like to direct my special thanks to Dr. Iman Atef Mandor, Professor of Clinical and Chemical pathology, Faculty of Medicine, Cairo University, for her invaluable help, fruitful advice, continuous support offered to me and guidance step by step till this essay finished.

I am want also to thank my family for supporting me throughout my life.



Pancé Mohamed

List of Abbreviations

5'-UTR	: 5' Untranslated region
ATP	: Adenosine tri-phosphate
BMI	: Body mass index
cAMP	: Cyclic adenosine monophosphate
COCs	: Combined oral contraceptives
CT	: Computed tomography
CX	: Cervix
D1-R	: Dopamine type 1 receptor
D2-R	: Dopamine type 2 receptor
DA	: Dopamine
dPRL	: Decidual prolactin
DR	: Dopamine receptor
E	: Estrogen
ECD	: Extra cellular domain
ECM	: Extracellular matrix
EGF	: Epidermal growth factor
ER	: Estrogen receptor
ET	: Endothelins
FGF-2	: Fibroblast growth factor-2
FGF-R	: Fibroblast growth factor receptor
FSH	: Follicle stimulating hormone
GABA	: Gamma Amino butyric acid γ
GH	: Growth hormone
GHR	: Growth hormone receptors
GIT	: Gasrointestinal tract
GnRH	: Gonadotropin releasing hormone
GnRHa	: Gonadotropin releasing hormone agonist
HCG	: Human chorionic gonadotropin
hGH	: Human growth hormone

List of Abbreviations (Cont.)

HPCM	: Human placental conditioned medium
HPF	: High power field
HRT	: Hormone replacement therapy
HSE	: Sonohysterography
ICD	: Intra cellular domain
IGF1-2	: Insulin growth factor
ILs	: Interleukins
IUD	: Intra-uterine device
IVF	: In vitro Fertilization
IVP	: Intravenous pyelography
Jak-stat	: Janus kinase signal transducer and activator of transcription
KDa	: Kilo Dalton
LH	: Lutinizing hormone
LIF	: Leukemia inhibiting factor
LPL	: Lipoprotein lipase
M	: Micron
MPA	: Medroxyprogesterone acetate
MRI	: Magnetic resonance imaging
mRNA	: Messenger ribonucleic acid
ng	: Nanogram
NMR	: Nuclear magnetic resonance
NSAIDs	: Non steroidal anti-inflammatory drugs
Ob/ Gyn	: Obstetric / Gynecology
OCS	: Oral contraceptives
P	: Progesteron
P53	: Tumour suppressor gene
PDGF	: Platelet-derived growth factor
PGs	: Prostaglandins

List of Abbreviations (Cont.)

PES	: Post-embolization syndrome
PI3K	: Phosphoinositide-3 kinase
PIF	: Prolactin inhibitory factor
Pit-1	: Pituitary- specific transcription factor
PKA	: Protein kinase A
PKC	: Protein kinase c
PL	: Placental lactogens
PRF	: Prolactin releasing factor
PRL	: Prolactin
PRLR	: Prolactin receptors
PTHrP	: Parathyroid hormone related peptide
PVA	: Polyvinyl alcohol
RIA	: Radioimmuno assay
RT-PCR	: Reverse Transcriptase – Polymerase chain reaction
RU 436	: Mifepristone
SERMs	: Selective estrogen receptor modulators
SIS	: Saline infusion sonography
SMCs	: smooth muscle cells
SOCS	: Suppressor of cytokine signaling
SPRMs	: Selective progesterone receptor modulators
TGF-B	: Transforming growth factor-B
TIDA	: Tuberoinfundibular neurons
TM	: Transmembrane domain
TNF- α	: Tumour necrosis factor- α
TRH	: Thyrotropin releasing hormone
TV	: Transvaginal
u/s	: Ultrasound
UAE	: Uterine artery embolization
UFE	: Uterine fibroid embolization
VEGF	: Vascular endothelial growth factor
VGCCs	: Voltage gated Ca ²⁺ channels
VIP	: Vasoactive intestinal peptide

List of Figures

Fig.	Subject	Page
1	Uterine Fibroid	4
2	Anatomical Classification Of Leiomyoma	15
3	Gross Picture Of Uterine Fibroid	17
4	Intravascular Leiomyomatosis Of The Uterus	18
5	Diagram of the human and rat PRL promoters, PRL genes	39
6	Schematic presentation of the PRLR gene, transcripts, and proteins in humans.	42
7	Effect of several physiological events on Prolactin secretion.	46
8	Diagram of the hypothalamo-pituitary system that regulates PRL release in humans and rats.	47
9	Diagnosis of hyperprolactinaemia in young women.	64
10(A)	Pie-Chart showing Frequency Distribution of Menstrual Cycle Pattern in Women of Group I [Fibroid Group]	88
10(B)	Bar-Chart showing Frequency Distribution of Different Forms of Abnormal Menstrual Cycle Pattern in Women of Group I [Fibroid Group]	88
11(A)	Pie-Chart showing Frequency Distribution of Fibroid-Related Pain in Women of Group I [Fibroid Group]	89
11(B)	Bar-Chart showing Frequency Distribution of Different Forms of Fibroid-Related Pain in Women of Group I [Fibroid Group]	89
12(A)	Pie-Chart showing Frequency Distribution of Pressure Symptoms in Women of Group I [Fibroid Group]	90

List of Figures

12(B)	Bar-Chart showing Frequency Distribution of Different Forms of Pressure Symptoms in Women of Group I [Fibroid Group]	90
13	Pie-Chart showing Frequency Distribution of Infertility in Women of Group I [Fibroid Group]	91
14(A)	Pie-Chart showing Frequency Distribution of Prior Miscarriages in Women of Group I [Fibroid Group]	92
14(B)	Bar-Chart showing Types of Distribution of Prior Miscarriages in Women of Group I [Fibroid Group]	92
15	Sonographic Features of Fibroid (No. of Lesions) in Women of Group I [Fibroid Group]	94
16	Sonographic Features of Fibroid (Type) in Women of Group I [Fibroid Group]	94
17	Sonographic Features of Fibroid (Site) in Women of Group I [Fibroid Group]	95
18	Bar-Chart showing Difference between Groups regarding Median Serum Prolactin	97
19	Scatter-Plot showing Correlation between Preoperative Serum Prolactin, and Size of Fibroid among Group I [Fibroid Group]	99
20	Scatter-Plot showing Correlation between Preoperative Serum Prolactin, and Duration of Fibroid-related Symptoms among Group I [Fibroid Group]	100
21	Bar-Chart showing Difference in Median Serum Prolactin According to No. of Fibroids	101
22	Bar- Chart showing Difference in Median Serum Prolactin According to Type of Fibroid	102
23	Bar-Chart showing Difference in Median Serum Prolactin according to Site of Fibroid	103

List of Tables

Table	Subject	Page
1	Leiomyoma – Associated Cytogenetic Changes	8
2	Relationships Of Patient Factors Leiomyoma Risk, and Steroid Hormones	10
3	Recommended Treatment Options For Women With Uterine Fibroid Tumors	25
4	Indication For The Medical Treatment Of Uterine Leiomyoma	25
5	Commonly Used Oral NSAIDs In Treatment Of Fibroid Associated Dysmenorrhea	26
6	Dosages Of Gonadotropin-Releasing Hormone Agonists	29
7	Complications For UAE Used For Treatment Of Fibroid	33
8	Potential causes of hyperprolactinaemia	61
9	Dopamine agonists commonly used in the treatment of hyperprolactinemia	66
10	Difference between Groups regarding Age and Parity	87
11	Frequency Distribution of Menstrual Cycle -related Symptoms in Women of Group I [Fibroid Group]	88
12	Frequency Distribution of pain-related Symptoms in Women of Group I [Fibroid Group]	89
13	Frequency Distribution of Pressure -related Symptoms in Women of Group I [Fibroid Group]	90
14	Frequency Distribution of Infertility in Women of Group I [Fibroid Group]	91

List of Tables (Cont.)

Table	Subject	Page
15	Frequency Distribution of Previous Miscarriage and recurrent fibroid in Women of Group I [Fibroid Group]	92
16	Duration of Symptoms in Women of Group I [Fibroid Group]	93
17	Sonographic Features of Fibroid in Women of Group I [Fibroid Group]	93
18	Difference between Groups regarding Serum Prolactin	96
19	Correlation between Serum Prolactin, Size of Fibroid, Duration of Symptoms, Age and Parity among Group I [Fibroid Group]	98
20	Difference in Serum Prolactin According to No. of Fibroids	101
21	Difference in Serum Prolactin According to Type of Fibroid	102
22	Difference in Serum Prolactin according to Site of Fibroid	103

List of Contents

	Page
Acknowledgment	--
Abstract	--
List of Abbreviations	i
List of Figures	v
List of Tables	vii
Introduction and Aim of the Work	1
Review of Literature	4
Chapter 1 : Uterine fibroid	4
Chapter 2 : Prolactin hormone in humans	37
Chapter 3 : Evidence of Correlations between prolactin and the Leiomyoma	70
Patients and Methods	81
Results	87
Discussion	104
Summary and conclusion	107
Recommendations	109
References	110
Arabic Summary	--

INTRODUCTION

Uterine fibroid (leiomyoma) is the most common benign uterine tumors in women of reproductive age which originates from the smooth muscle layer and the accompanying connective tissue of the uterus (*Jolley, 2009*).

Although the incidence and natural history of the uterine fibroids are not fully understood. Uterine fibroid formation and development varies with age, increasing in the middle and late reproductive period and with ethnic origin, with African American women being disproportionately affected (*Hoffman, 2009*).

Many studies have suggested that uterine leiomyomas are monoclonal tumors derived from a single neoplastic myometrial cell, and neoplastic transformation of myometrium to leiomyosarcoma occurs in less than 1% of fibroids (*Tai et al., 2003*).

prolactin (**PRL**) is trophic hormone produced mainly by the pituitary gland but also secreted by extrapituitary site as (uterus, colon, etc). In addition to the decidualized endometrium of the late luteal phase and of pregnancy the human myometrium has been proposed as a second source of **uterine PRL** (*Gellersen et al., 1991*).

Many studies showed increasing evidence of **PRL** effects and say that **PRL** plays a role in several types of cancer in the reproductive and non reproductive tissues via local production or accumulation (*Ben-Jonathan et al., 2002*).

PRL production may be a potential marker for detecting an early occult fibroid tumor or for gauging the effectiveness of therapy (*Flake et al., 2003*).

Considering **PRL** as an active participant in tumorigenesis should inspire and encourage the development of novel therapies aimed to reducing PRL production or by blocking its receptors (*Somiglanaa et al., 2007*).

AIM OF THE WORK

A case control study aimed to evaluate the possible relationship between circulating levels of **PRL** with **uterine fibroid(s)** and the possibility of these parameters to be used as a diagnostic marker of the tumor.

Uterine fibroid

Definition:

Uterine fibroid also called (uterine leiomyoma, myoma, fibromyoma, leiofibromyoma and fibroma). It is a benign tumor that originates from the smooth muscle layer (myometrium) and the accompanying connective tissue of the uterus (**Fig 1**) (*Jolley, 2009*).



Fig. (1): Uterine Fibroids (leiomyomas) (*Jolley, 2009*).

Incidence (prevalence):

Fibroids are the most common benign solid pelvic tumors in females. Fibroids tend to develop in women in their thirties and forties. Although estimations of the number of women whose are affected vary considerably with figures ranging from 20% to 70%, it is generally accepted that about one in three women will develop fibroids (*Cornforth, 2009*).